Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Eliem Therapeutics Inc.

    NASDAQ: ELYM · Real-Time Price · USD
    5.11
    -0.05 (-0.97%)
    At close: Oct 02, 2024, 8:00 PM

    Eliem Therapeutics Statistics

    Share Statistics

    Eliem Therapeutics has 67.06M shares outstanding. The number of shares has increased by 125.4% in one year.

    Shares Outstanding

    n/a
    		 67.06M

    Shares Change (YoY)

    n/a
    		 125.4%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 48,972

    FTD / Avg. Volume

    n/a
    		 9.42%

    Short Selling Information

    Short Interest

    n/a
    		 n/a

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 n/a

    Valuation Ratios

    The PE ratio is -2.07 and the forward PE ratio is null. Eliem Therapeutics's PEG ratio is 0.08.

    PE Ratio

    n/a
    		 -2.07

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 0.68

    P/FCF Ratio

    n/a
    		 -3.54

    PEG Ratio

    n/a
    		 0.08
    Financial Ratio History

    Enterprise Valuation

    Eliem Therapeutics has an Enterprise Value (EV) of -19.9M.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 1.46

    EV / EBIT

    n/a
    		 0.97

    EV / FCF

    n/a
    		 0.97

    Financial Position

    The company has a current ratio of 38.92, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 38.92

    Quick Ratio

    n/a
    		 38.92

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.03

    Debt / FCF

    n/a
    		 -0.02

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is -32.64% and Return on Invested Capital is -19.87%.

    Return on Equity

    n/a
    		 -32.64%

    Return on Assets

    n/a
    		 -31.79%

    Return on Invested Capital

    n/a
    		 -19.87%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-3,902,111.11

    Employee Count

    n/a
    		 9

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -21.47K

    Effective Tax Rate

    n/a
    		 0.06%

    Stock Price Statistics

    The stock price has increased by 39.62% in the last 52 weeks. The beta is -0.38, so Eliem Therapeutics's price volatility has been lower than the market average.

    Beta

    n/a
    		 -0.38

    52-Week Price Change

    n/a
    		 39.62%

    50-Day Moving Average

    n/a
    		 6.13

    200-Day Moving Average

    n/a
    		 5.58

    Relative Strength Index (RSI)

    n/a
    		 25.78

    Average Volume (20 Days)

    n/a
    		 519,722

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -21.47M

    Net Income

    n/a
    		 -35.12M

    EBITDA

    n/a
    		 -13.65M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -1.3
    Full Income Statement

    Balance Sheet

    The company has 93.11M in cash and 349K in debt, giving a net cash position of 92.76M.

    Cash & Cash Equivalents

    n/a
    		 93.11M

    Total Debt

    n/a
    		 349K

    Net Cash

    n/a
    		 92.76M

    Retained Earnings

    n/a
    		 -155.98M

    Total Assets

    n/a
    		 226.02M

    Working Capital

    n/a
    		 222.26M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -20.6M and capital expenditures 0, giving a free cash flow of -20.6M.

    Operating Cash Flow

    n/a
    		 -20.6M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -20.6M

    FCF Per Share

    n/a
    		 -0.76
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    ELYM does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -48.2%

    FCF Yield

    n/a
    		 -28.27%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for ELYM.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 53.65

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist